CNS Pharmaceuticals Announces Reverse Stock Split

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The biopharmaceutical company's stock will continue trading on the Nasdaq Capital Market under the same symbol "CNSP" but with a new CUSIP number: 18978H508.

Under this reverse split, every 12 shares will be automatically combined into one share, with proportional adjustments made to outstanding warrants and equity-based awards. The company's authorized shares will be reduced to 25 million, while maintaining a par value of $0.001 per share. Stockholders entitled to fractional shares will receive cash payments instead.

Positive

• Potential to maintain Nasdaq listing compliance through higher share price
• No change to stockholders' proportional equity ownership

Negative

• Significant reduction in outstanding shares could impact stock liquidity
• Cash payments required for fractional shares may force small positions to close

HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-12 reverse split of its common stock. Beginning on July 22, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP" but will trade under the following new CUSIP number: 18978H508.

As a result of the reverse stock split, every 12 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock. Outstanding warrants, equity-based awards and other outstanding equity rights will be proportionately adjusted by dividing the shares of common stock underlying the securities by 12 and multiplying the exercise/conversion price, as the case may be, by 12. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a cash payment in lieu of a fractional share. The par value of the common stock will remain unchanged at $0.001 per share after the reverse split. The number of authorized shares of common stock will be proportionately reduced to 25 million shares. The reverse split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse split results in some stockholders owning a fractional share as described above.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the ratio of CNS Pharmaceuticals (CNSP) reverse stock split announced for July 2025?

CNS Pharmaceuticals announced a 1-for-12 reverse stock split, meaning every 12 shares will be combined into one share.

When will CNSP's reverse stock split take effect?

The reverse stock split will take effect on July 22, 2025, with the stock continuing to trade on Nasdaq under the symbol 'CNSP' but with a new CUSIP number.

How will CNSP's reverse split affect stockholders' ownership percentages?

The reverse split will not alter any stockholder's percentage interest in the company's equity, except for minor adjustments due to fractional shares.

What happens to fractional shares in CNSP's reverse stock split?

Stockholders who would receive fractional shares will receive cash payments instead, as no fractional shares will be issued.

How will CNSP's reverse split affect the company's authorized shares?

The number of authorized shares will be proportionately reduced to 25 million shares, while maintaining a par value of $0.001 per share.